ARWR catalyst calendar

ARROWHEAD PHARMACEUTICALS, INC.

Upcoming catalysts
13
Cash runway
Cash generating
Phase 3 programs
8

ARROWHEAD PHARMACEUTICALS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 1, 2026, a projected date rather than a confirmed one. There are 13 upcoming events on record.

ARROWHEAD PHARMACEUTICALS, INC. generates cash from operations, so a burn-based runway figure does not apply.

Across 37 concluded trials, 62% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 1, 2026 est. Next quarterly earnings (projected) Earnings —
December 15, 2026 Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 Trial Milestone Phase 1
February 15, 2027 A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus Trial Milestone Phase 1/Phase 2
June 15, 2027 Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease Trial Milestone Phase 1/Phase 2
July 15, 2027 Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia Trial Milestone Phase 1/Phase 2
August 20, 2027 A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) Trial Milestone Phase 3
September 17, 2027 A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus Trial Milestone Phase 1/Phase 2
December 15, 2027 Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma Trial Milestone Phase 2
July 1, 2028 A First-In-Human Study of ARO-033 in Adult Participants Trial Milestone Phase 1
July 15, 2028 Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia Trial Milestone Phase 3
July 15, 2028 Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia Trial Milestone Phase 3
March 15, 2029 Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis Trial Milestone Phase 3
October 15, 2029 A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis Trial Milestone Phase 2

Track ARWR alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open ARWR in the tracker

Recent history

DateEventTypePhase
August 4, 2026 Quarterly results filed (8-K) Earnings —
June 17, 2026 Study of Plozasiran in Adults With Severe Hypertriglyceridemia Trial Milestone Phase 3
June 16, 2026 8-K filed: Leadership change Corporate —
June 12, 2026 Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia Trial Milestone Phase 3
June 1, 2026 Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia Trial Milestone Phase 3
May 7, 2026 Quarterly results filed (8-K) Earnings —
February 5, 2026 Quarterly results filed (8-K) Earnings —
January 12, 2026 8-K filed: Material agreement Corporate —
January 9, 2026 8-K filed: Material agreement, Other event Corporate —
January 6, 2026 8-K filed: Reg FD disclosure, Other event Filing —
November 25, 2025 Quarterly results filed (8-K) Earnings —
November 18, 2025 8-K filed: Other event Filing —
September 22, 2025 Study of ARO-APOC3 in Adults With Dyslipidemia Trial Milestone Phase 2
September 12, 2025 8-K filed: Other event Filing —
September 11, 2025 8-K filed: Other event Filing —
September 10, 2025 Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease Trial Milestone Phase 1/Phase 2
September 5, 2025 Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis Trial Milestone Phase 1/Phase 2
September 2, 2025 8-K filed: Material agreement Corporate —
August 7, 2025 Quarterly results filed (8-K) Earnings —
May 12, 2025 Quarterly results filed (8-K) Earnings —
April 16, 2025 Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease Trial Milestone Phase 1/Phase 2
April 15, 2025 8-K filed: Leadership change Corporate —
March 31, 2025 Study of ARO-CFB in Adult Healthy Volunteers Trial Milestone Phase 1
November 12, 2024 Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease Trial Milestone Phase 1/Phase 2
April 29, 2024 Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) Trial Milestone Phase 3
February 8, 2024 Study of ARO-RAGE in Healthy Subjects Trial Milestone Phase 1
May 2, 2023 Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH) Trial Milestone Phase 2
March 9, 2023 Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia Trial Milestone Phase 2
February 10, 2023 Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia Trial Milestone Phase 2
August 30, 2022 Study of ARO-ANG3 in Adults With Mixed Dyslipidemia Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.